Abstract
Bronchopulmonary dysplasia (BPD) is a chronic lung disease specifically affecting preterm infants, often exacerbated by hyperoxia-induced lung injury. This study investigates the role of the PVT1/IL-33 axis in BPD pathogenesis. Using mouse and human lung alveolar epithelial cell models, researchers identified that the long non-coding RNA (lncRNA) PVT1 recruits the m6A reader protein YTHDC1 to stabilize IL-33 mRNA through N6-methyladenosine (m6A) modification. Silencing PVT1 was found to suppress apoptosis and improve lung function, suggesting that the PVT1/IL-33 axis is a potential therapeutic target for hyperoxia-induced lung injury in BPD.
Introduction
Bronchopulmonary dysplasia (BPD) remains a significant challenge in neonatal intensive care. While life-saving, oxygen therapy can lead to hyperoxia-induced lung injury, characterized by the apoptosis of lung alveolar epithelial cells and impaired lung development. Recent advances in epitranscriptomics have highlighted the role of RNA modifications, particularly m6A methylation, in regulating gene expression and disease progression. This study explores how the lncRNA PVT1 and the cytokine IL-33 are regulated by m6A modifications in the context of BPD.
Epitranscriptomic Profiling in BPD
To understand the molecular landscape of hyperoxia-induced injury, researchers performed an epitranscriptomic microarray analysis comparing normal mice lungs with those stimulated by hyperoxia. The analysis revealed a significant shift in the RNA methylation landscape, with 817 upregulated and 626 downregulated mRNAs. Notably, both IL-33 and PVT1 exhibited significantly increased m6A RNA methylation levels and elevated expression in the hyperoxia-stimulated group.
The PVT1/YTHDC1/IL-33 Axis
The study identified a specific signaling mechanism where PVT1 acts as a molecular scaffold. PVT1 recruits the m6A reader protein YTHDC1 to the IL-33 mRNA. This recruitment facilitates the m6A modification of IL-33, which enhances its stability and leads to higher protein expression. Elevated IL-33 levels, in turn, promote apoptosis in alveolar epithelial cells.
Experimental Results and Therapeutic Potential
In vitro experiments using MLE12 (mouse) and A549 (human) lung epithelial cells confirmed that hyperoxia triggers a substantial increase in PVT1 and IL-33 expression. Silencing PVT1 using shRNA significantly reduced apoptosis rates and shifted the balance of apoptotic markers, decreasing Bax and increasing Bcl-2 levels.
In vivo, silencing PVT1 in a BPD mouse model led to measurable improvements in lung architecture. Parameters such as radial alveolar count increased, indicating a rescue of lung development from hyperoxic damage. RNA-binding protein immunoprecipitation (RIP) assays further confirmed that silencing PVT1 reduced the binding of YTHDC1 to IL-33 by over 50%, validating the proposed mechanism.
Conclusion
The findings demonstrate that the PVT1/YTHDC1/IL-33 axis plays a critical role in hyperoxia-induced lung injury. By recruiting YTHDC1 to mediate the m6A modification and stabilization of IL-33, PVT1 exacerbates alveolar cell apoptosis. Targeting this axis, particularly through the silencing of PVT1, offers a promising therapeutic strategy to alleviate the severity of BPD in preterm infants. Future research may further elucidate the upstream "writers" of these m6A marks and explore the clinical feasibility of targeted lncRNA therapies.
Summary updated